Androgen Receptor Expression in Triple Negative Breast Cancer - Study from a Tertiary Health Care Center in South India

Abstract Background: The treatment of breast cancer is based on a multi-modality approach. Analysis of the hormone receptor has been accepted as a standard procedure, in the routine management of breast cancer patients. Triple negative breast cancers (TNBCs) are those which are negative for expression of all three markers, i.e., estrogen receptor, progesterone receptor (PR), and human epidermal growth factor receptor. High expression of Ki-67, a proliferation index, has been associated with a worse prognosis in TNBC. TN cancers are aggressive in nature as they do not respond to routine targeted therapy. The role of the androgen receptor (AR) in breast carcinomas is important as AR has been suggested as a potential therapeutic target. We did this study to assess AR immunoreactivity in TNBCs and correlate with Ki-67 index. Materials and Methods: In this study group, there were 45 cases of TN invasive breast carcinomas. These tumors were analyzed with respect to AR and Ki-67 index. Results: Of 45 TN breast carcinomas analyzed, 42 were infiltrating duct cell carcinoma (IDCC) of not otherwise specified type. There were one medullary and two metaplastic carcinomas. The median age was 46 years. AR was positive in 20% (9/45) of cases. All the AR positive cases were an IDCC (nos). Out of the nine AR positive cases, six showed positivity for Ki-67. The statistical analysis using Pearson's Chi-squared method did not reveal any correlation between AR and Ki-67 index (P = 0.574). Conclusion: Although our study did not reveal any statistically significant correlation between AR and Ki-67 index, assessment of AR status in TNBC patients is desirable as it may help to develop a targeted therapy in future in these aggressive cancers.

[1]  A. Chowhan,et al.  Hormone receptor status (estrogen receptor, progesterone receptor), human epidermal growth factor-2 and p53 in South Indian breast cancer patients: A tertiary care center experience , 2015, Indian Journal of Medical and Paediatric Oncology.

[2]  R. Saxena,et al.  Triple negative breast cancer in people of North East India: critical insights gained at a regional cancer centre. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[3]  Myles A Brown,et al.  Importance of Breast Cancer Subtype in the Development of Androgen-Receptor-Directed Therapy , 2014, Current Breast Cancer Reports.

[4]  Andres Forero,et al.  Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer , 2013, Clinical Cancer Research.

[5]  Yan Peng,et al.  Decreased androgen receptor expression is associated with distant metastases in patients with androgen receptor-expressing triple-negative breast carcinoma. , 2012, American journal of clinical pathology.

[6]  D. Hicks,et al.  Expression of the Androgen Receptor and its Correlation with Molecular Subtypes in 980 Chinese Breast Cancer Patients , 2011, Breast cancer : basic and clinical research.

[7]  R. Tamimi,et al.  Androgen Receptor Expression in Breast Cancer in Relation to Molecular Phenotype: Results from the Nurses’ Health Study , 2011, Modern Pathology.

[8]  Jian Chen,et al.  [Expression of androgen receptor in breast carcinoma and its relationship with estrogen receptor, progesterone receptor and HER2 status]. , 2010, Zhonghua bing li xue za zhi = Chinese journal of pathology.

[9]  F. Labrie,et al.  Immunocytochemical Localization of Sex Steroid Hormone Receptors in Normal Human Mammary Gland , 2010, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[10]  T. Traina,et al.  Triple-Negative Breast Cancer: Role of the Androgen Receptor , 2010, Cancer journal.

[11]  Z. Nahleh Androgen receptor as a target for the treatment of hormone receptor-negative breast cancer: an unchartered territory. , 2008, Future oncology.

[12]  H. Denk,et al.  Androgen receptors frequently are expressed in breast carcinomas , 2003, Cancer.